Recent developments highlight RedHill's strategic partnerships, licensing deals, clinical trial progress, and legal outcomes that shape its business and financial position.

• RedHill won a final and enforceable $8 million court judgment against Kukbo, unlocking potential legal recovery [N1].
• The company announced plans to submit a UK Marketing Authorization Application for Talicia, referencing FDA approval, aiming to expand global market access [N2].
• RedHill licensed RHB-102 (Bekinda) to Hyloris Pharmaceuticals for worldwide commercialization excluding North America, with potential milestone payments and royalties [N3].
• A Phase 2 trial for advanced prostate cancer treatment combining opaganib and darolutamide was launched, with ongoing recruitment and expanded sites [N4].
• Preclinical studies showed opaganib's radioprotective activity and potential in oncology indications including neuroblastoma and triple-negative breast cancer [N5].
• RedHill was awarded a judgment of approximately $8 million plus costs in legal proceedings against Kukbo, now final and eligible for enforcement [N6].

RedHill has transformed its Talicia business through a strategic joint venture with Cumberland Pharmaceuticals, enabling expanded U.S. commercialization and revenue sharing. Licensing of RHB-102 to Hyloris Pharmaceuticals for ex-North America markets provides potential milestone payments and royalties. The company is advancing clinical programs with opaganib in oncology indications, supported by Bayer collaboration and preclinical data in multiple cancers. Positive FDA feedback on RHB-204 for Crohn's disease and collaborations for diagnostic development represent pipeline progress. Legal victories, including a $10.5 million judgment, and improved financial position with positive equity and cash balances support operational resilience.

RedHill faces risks from ongoing operating losses and limited current revenues from continuing operations. The company's liquidity ratios indicate constrained short-term financial flexibility. Clinical development programs carry inherent risks of regulatory and trial outcomes. The company depends on strategic partnerships and licensing deals for revenue generation, which may not materialize as anticipated. Legal judgment collections remain subject to realization uncertainty. Market acceptance and competitive dynamics in gastrointestinal and oncology therapeutic areas may challenge commercial success. The company operates in a highly regulated environment with risks related to approvals, reimbursement, and intellectual property protection.

RedHill's moat is supported by its FDA-approved proprietary product Talicia®, which benefits from eight years of U.S. market exclusivity under Qualified Infectious Disease Product designation and patent protection extending to 2042. The company's strategic joint venture with Cumberland Pharmaceuticals for Talicia's U.S. commercialization provides operational scale and shared revenue streams. Licensing agreements, such as the ex-North America deal for RHB-102, offer potential milestone and royalty income. The company's pipeline includes novel therapeutic candidates with orphan drug designations and government collaborations, which may provide competitive differentiation. However, the biopharmaceutical industry is characterized by regulatory, clinical, and commercial risks that can impact competitive positioning.

• Clinical and Regulatory Risk: RedHill's development programs may not achieve successful clinical trial outcomes or regulatory approvals, which could delay or prevent commercialization of its therapeutic candidates.
• Commercialization and Market Acceptance Risk: The company's ability to successfully commercialize Talicia and other products depends on market acceptance, competition, and effective marketing and sales execution.
• Financial and Liquidity Risk: Operating losses and limited current revenues may constrain financial resources, with liquidity ratios indicating short-term obligations exceed current assets as of mid-2025.
• Partnership and Licensing Risk: RedHill relies on strategic partnerships and licensing agreements for revenue and commercialization; failure to maintain or expand these relationships could impact business performance.
• Legal and Collection Risk: Although RedHill has won a significant court judgment, collection of awarded amounts remains subject to future realization and may not be guaranteed.

• RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology.
• The company promotes Talicia®, an FDA-approved gastrointestinal drug for treatment of Helicobacter pylori infection in adults, with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals.
• Talicia is a fixed-dose oral capsule combining two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved in the U.S. and UAE, with patent protection through 2042 in the U.S. and additional patents worldwide.
• In 2025, RedHill formed Talicia Holdings Inc. (THI), a 70%-owned joint venture with Cumberland Pharmaceuticals, transferring Talicia commercial operations to THI, which shares net revenues equally with Cumberland in the U.S.
• RedHill licensed RHB-102 (Bekinda®) to Hyloris Pharmaceuticals for worldwide commercialization excluding North America, with potential milestone payments up to $60 million plus royalties.
• The company expanded Talicia's Middle East licensing agreement in 2025, receiving upfront and milestone payments plus tiered royalties on net sales.
• RedHill has a pipeline including opaganib (a sphingosine kinase-2 inhibitor) in multiple oncology and inflammatory indications, RHB-204 for Crohn's disease, and RHB-107 (upamostat) for COVID-19 and other indications.
• Opaganib is in a Bayer-supported Phase 2 study in combination with darolutamide for advanced prostate cancer (mCRPC), with ongoing recruitment and expanded sites.
• Preclinical data support opaganib's potential in chronic lymphocytic leukemia, neuroblastoma, and triple-negative breast cancer, with orphan drug designations in oncology.
• RedHill reported positive FDA feedback on RHB-204's pathway to approval for Crohn's disease and has collaborations for MAP detection diagnostics.
• The company has a $10 million line of credit with Alumni Capital LP allowing sale of ADSs under an Any Market Purchase Agreement.
• RedHill won a final and enforceable New York Supreme Court judgment of approximately $10.5 million plus costs against Kukbo Co. Ltd., with collection subject to future realization.
• For the year ended December 31, 2025, continuing operations revenue was $0.3 million from the Hyloris license; operating loss was $7.9 million; net loss from continuing operations was $8.1 million; net income from discontinued operations was $7.7 million.
• Talicia generated approximately $8.9 million in U.S. net revenues in 2025 including Cumberland's post-closing revenues, and approximately $1.9 million in ex-U.S. licensing and royalties.
• As of June 30, 2025, RedHill had cash and cash equivalents of $2.87 million, current assets of $12.56 million, current liabilities of $22.29 million, a current ratio of 0.56, and a cash ratio of 0.13.
• As of December 31, 2025, the company had positive equity of $4.3 million compared to a capital deficiency of $4.7 million at year-end 2024, and a cash balance of $4.1 million.
• RedHill's R&D expenses increased to $2.0 million in 2025 from $1.6 million in 2024, mainly due to clinical activities; general and administrative expenses increased to $6.2 million, primarily due to legal expenses related to Kukbo litigation.
• The company is pursuing additional commercial products through licensing, promotion, acquisitions, joint ventures, and other business combinations in the U.S. and other jurisdictions.
• RedHill's business model includes strategic partnerships, licensing deals, clinical development, and commercialization of specialty pharmaceutical products primarily in gastrointestinal, infectious, and oncology areas.